1. Home
  2. PCRX vs PML Comparison

PCRX vs PML Comparison

Compare PCRX & PML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • PML
  • Stock Information
  • Founded
  • PCRX 2006
  • PML 2002
  • Country
  • PCRX United States
  • PML United States
  • Employees
  • PCRX N/A
  • PML N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • PML Investment Managers
  • Sector
  • PCRX Health Care
  • PML Finance
  • Exchange
  • PCRX Nasdaq
  • PML Nasdaq
  • Market Cap
  • PCRX 604.7M
  • PML 581.8M
  • IPO Year
  • PCRX 2011
  • PML N/A
  • Fundamental
  • Price
  • PCRX $22.36
  • PML $8.16
  • Analyst Decision
  • PCRX Buy
  • PML
  • Analyst Count
  • PCRX 10
  • PML 0
  • Target Price
  • PCRX $27.60
  • PML N/A
  • AVG Volume (30 Days)
  • PCRX 810.1K
  • PML 188.0K
  • Earning Date
  • PCRX 02-27-2025
  • PML 01-01-0001
  • Dividend Yield
  • PCRX N/A
  • PML 5.65%
  • EPS Growth
  • PCRX N/A
  • PML N/A
  • EPS
  • PCRX N/A
  • PML N/A
  • Revenue
  • PCRX $694,957,000.00
  • PML N/A
  • Revenue This Year
  • PCRX $4.83
  • PML N/A
  • Revenue Next Year
  • PCRX $2.16
  • PML N/A
  • P/E Ratio
  • PCRX N/A
  • PML N/A
  • Revenue Growth
  • PCRX 4.40
  • PML N/A
  • 52 Week Low
  • PCRX $11.16
  • PML $6.92
  • 52 Week High
  • PCRX $34.01
  • PML $9.46
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 70.92
  • PML 43.46
  • Support Level
  • PCRX $18.18
  • PML $7.97
  • Resistance Level
  • PCRX $22.36
  • PML $8.30
  • Average True Range (ATR)
  • PCRX 1.13
  • PML 0.10
  • MACD
  • PCRX 0.30
  • PML 0.03
  • Stochastic Oscillator
  • PCRX 93.11
  • PML 57.58

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

About PML Pimco Municipal Income Fund II of Beneficial Interest

PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.

Share on Social Networks: